Goldman Sachs
ARIA

Goldman Sachs’s Ariad Pharmaceuticals Inc ARIA Stock Holding History

Goldman Sachs’s Portfolio ARIA Stock Details ARIA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q1 		– Sell
-103,800
Closed -$1.29M – 7243
2016
Q4 		$1.29M Sell
103,800
-43,500
-30% -$524K ﹤0.01% 4238
2016
Q3 		$2.02M Buy
147,300
+111,000
+306% +$1.11M ﹤0.01% 3825
2016
Q2 		$268K Sell
36,300
-83,400
-70% -$626K ﹤0.01% 5441
2016
Q1 		$765K Buy
119,700
+48,400
+68% +$271K ﹤0.01% 4326
2015
Q4 		$446K Buy
71,300
+12,200
+21% +$80.1K ﹤0.01% 5023
2015
Q3 		$345K Sell
59,100
-49,700
-46% -$383K ﹤0.01% 5479
2015
Q2 		$900K Buy
108,800
+50,700
+87% +$448K ﹤0.01% 4638
2015
Q1 		$479K Sell
58,100
-70,600
-55% -$522K ﹤0.01% 5174
2014
Q4 		$884K Buy
128,700
+41,300
+47% +$258K ﹤0.01% 4705
2014
Q3 		$472K Sell
87,400
-222,300
-72% -$1.3M ﹤0.01% 5325
2014
Q2 		$1.97M Buy
309,700
+29,800
+11% +$205K ﹤0.01% 4006
2014
Q1 		$2.26M Sell
279,900
-85,600
-23% -$667K ﹤0.01% 3866
2013
Q4 		$2.49M Buy
365,500
+194,200
+113% +$1.05M ﹤0.01% 3850
2013
Q3 		$3.15M Buy
171,300
+4,000
+2% +$77.7K ﹤0.01% 3443
2013
Q2 		$2.93M Buy
+167,300
New +$2.97M ﹤0.01% 3310

Other funds holding ARIA

FPF
FNY Partners Fund New York $185M AUM 32.59% 1-Year Est. Return

Goldman Sachs's ARIA Position: Q1 2017 in Review

Goldman Sachs sold out of Ariad Pharmaceuticals Inc (ARIA) in Q1 2017, closing a stake of 1,394,100 shares — an estimated $17.3M sold.

Goldman Sachs first reported a position in ARIA in Q2 2013 and held it in 15 quarters. The position peaked at $149M in Q3 2013. 1 fund tracked by Wall St. Rank holds ARIA as of Q1 2017.

  • Goldman Sachs reported no remaining Ariad Pharmaceuticals Inc position as of Q1 2017 after selling out during the quarter.
  • Goldman Sachs sold 1,394,100 Ariad Pharmaceuticals Inc shares in Q1 2017, an estimated $17.3M.
  • Goldman Sachs first reported a position in Ariad Pharmaceuticals Inc in Q2 2013 and held it in 15 quarters.
  • Goldman Sachs's Ariad Pharmaceuticals Inc position peaked at $149M in Q3 2013.
  • 1 fund tracked by Wall St. Rank held Ariad Pharmaceuticals Inc as of Q1 2017.

Based on Goldman Sachs's 13F filing for Q1 2017, filed 15 May 2017.